<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7808749</article-id><article-id pub-id-type="pmid">33430657</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1842390</article-id><article-id pub-id-type="publisher-id">1842390</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations</article-title><alt-title alt-title-type="left-running-head">R. Sasidharan et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sasidharan</surname><given-names>Rani</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="author-notes" rid="FN0002"/></contrib><contrib contrib-type="author"><name><surname>Eom</surname><given-names>Bo Hyun</given-names></name><xref ref-type="aff" rid="AF0003">c</xref><xref ref-type="author-notes" rid="FN0002"/></contrib><contrib contrib-type="author"><name><surname>Heo</surname><given-names>Jeong Hyun</given-names></name><xref ref-type="aff" rid="AF0003">c</xref><xref ref-type="author-notes" rid="FN0002"/></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jong Eun</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>Abdelgawad</surname><given-names>Mohamed A.</given-names></name><xref ref-type="aff" rid="AF0004">d</xref><xref ref-type="aff" rid="AF0005">e</xref></contrib><contrib contrib-type="author"><name><surname>Musa</surname><given-names>Arafa</given-names></name><xref ref-type="aff" rid="AF0006">f</xref><xref ref-type="aff" rid="AF0007">g</xref></contrib><contrib contrib-type="author"><name><surname>Gambacorta</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="AF0008">h</xref></contrib><contrib contrib-type="author"><name><surname>Nicolotti</surname><given-names>Orazio</given-names></name><xref ref-type="aff" rid="AF0008">h</xref></contrib><contrib contrib-type="author"><name><surname>Manju</surname><given-names>Sreedharannair Leelabaiamma</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="corresp" rid="AN0003"/></contrib><contrib contrib-type="author"><name><surname>Mathew</surname><given-names>Bijo</given-names></name><xref ref-type="aff" rid="AF0009">i</xref><xref ref-type="corresp" rid="AN0002"/><xref ref-type="author-notes" rid="FN0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7203-3712</contrib-id><name><surname>Kim</surname><given-names>Hoon</given-names></name><xref ref-type="aff" rid="AF0003">c</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>College of Pharmaceutical Science, Government T.D. Medical College</institution>, <city>Alappuzha</city>, <country>India</country></aff><aff id="AF0002"><label>b</label><institution>Organic Chemistry Division, SAS, VIT University</institution>, <city>Vellore</city>, <country>India</country></aff><aff id="AF0003"><label>c</label><institution>Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University</institution>, <city>Suncheon</city>, <country>Republic of Korea</country></aff><aff id="AF0004"><label>d</label><institution>Pharmaceutical Chemistry Department, College of Pharmacy, Jouf University</institution>, <city>Sakaka</city>, <country>Saudi Arabia</country></aff><aff id="AF0005"><label>e</label><institution>Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University</institution>, <city>Beni Suef</city>, <country>Egypt</country></aff><aff id="AF0006"><label>f</label><institution>Department of Pharmacogonosy, College of Pharmacy, Jouf University</institution>, <city>Sakaka</city>, <country>Saudi Arabia</country></aff><aff id="AF0007"><label>g</label><institution>Department of Pharmacogonosy, Al-Azhar University</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0008"><label>h</label><institution>Dipartimento di Farmacia&#x02014;Scienze del Farmaco, Universit&#x000e0; degli Studi di Bari &#x0201c;Aldo Moro&#x0201d;</institution>, <city>Bari</city>, <country>Italy</country></aff><aff id="AF0009"><label>i</label><institution>Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy</institution>, <city>Palakkad</city>, <country>India</country></aff></contrib-group><author-notes><fn id="FN0002"><label><sup>#</sup></label><p>These authors contributed equally to this work.</p></fn><fn id="FN0001"><label>*</label><p>Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India.</p></fn><fn id="AUFN1"><p content-type="appended text">Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1842390"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001">CONTACT Hoon Kim <email>hoon@sunchon.ac.kr</email><institution>Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University</institution>, <city>Suncheon</city><postal-code>57922</postal-code>, <country>Republic of Korea</country></corresp><corresp id="AN0002">Bijo Mathew <email>bijomathew@aims.amrita.edu</email>&#x000a0;Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India</corresp><corresp id="AN0003">Sreedharannair Leelabaiamma Manju <email>slmanju@vit.ac.in</email><institution>Organic Chemistry Division, SAS, VIT University</institution>, <city>Vellore</city>, <country>India</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>12</day><month>1</month><year>2021</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="19">188</fpage><lpage>197</lpage><permissions><copyright-statement>&#x000a9; 2021 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1842390.pdf"/><abstract><title>Abstract</title><p>Nine compounds (<bold>MO1&#x02013;MO9</bold>) containing the morpholine moiety were assessed for their inhibitory activities against monoamine oxidases (MAOs) and acetylcholinesterase (AChE). Most of the compounds potently inhibited MAO-B; <bold>MO1</bold> most potently inhibited with an IC<sub>50</sub> value of 0.030&#x02009;&#x000b5;M, followed by <bold>MO7</bold> (0.25&#x02009;&#x000b5;M). <bold>MO5</bold> most potently inhibited AChE (IC<sub>50</sub> = 6.1&#x02009;&#x000b5;M), followed by <bold>MO9</bold> (IC<sub>50</sub> = 12.01&#x02009;&#x000b5;M) and <bold>MO7</bold> most potently inhibited MAO-A (IC<sub>50</sub> = 7.1&#x02009;&#x000b5;M). <bold>MO1</bold> was a reversible mixed-type inhibitor of MAO-B (<italic>K<sub>i</sub></italic> = 0.018&#x02009;&#x000b5;M); <bold>MO5</bold> reversibly competitively inhibited AChE (<italic>K<sub>i</sub></italic> = 2.52&#x02009;&#x000b5;M); and <bold>MO9</bold> reversibly noncompetitively inhibited AChE (<italic>K<sub>i</sub></italic> = 7.04&#x02009;&#x000b5;M). <bold>MO1</bold>, <bold>MO5</bold> and <bold>MO9</bold> crossed the blood&#x02013;brain barrier, and were non-toxic to normal VERO cells. These results show that <bold>MO1</bold> is a selective inhibitor of MAO-B and that <bold>MO5</bold> is a dual-acting inhibitor of AChE and MAO-B, and that both should be considered candidates for the treatment of Alzheimer&#x02019;s disease.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Morpholine-containing chalcone</kwd><kwd>monoamine oxidase</kwd><kwd>acetylcholinesterase</kwd><kwd>dual-acting inhibitor</kwd><kwd>Docking analysis</kwd></kwd-group><counts><fig-count count="8"/><table-count count="3"/><page-count count="10"/><word-count count="5082"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Due to the extreme complexities of brain systems and their diverse dysfunctions, research focus is being directed towards the design of multi-target directed ligands (MTDLs)<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. In fact, it has been suggested that functional equilibrium of brain after a neurologic disorder is unlikely to be achieved by focussing on a single molecular target<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. The major challenge presented by the development of MTDLs is to preserve balance between the effects drugs have by acting at their individual molecular targets<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>. On the other hand, some ligands can target two or more specific entities within numerous biological networks. The likelihood of successful MTDL design can be enhanced by considering the design of molecular scaffolds via suitable molecular hybridisation and by understanding the pathophysiologies of multifaceted diseases. The design process can be accelerated by selecting pharmacophores based on pre-clinical studies, emphasising structure&#x02013;activity relationships (SARs) and by performing <italic>in silico</italic>-based virtual screening<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>.</p><p>Monoamine oxidases (MAOs) play prominent roles in the inactivations of various biogenic amines in central and peripheral tissues. The isoenzymes of MAO-A and MAO-B are considered major therapeutic targets in various neuropsychiatric illnesses and neurodegenerative disorders like Alzheimer&#x02019;s disease (AD) and Parkinson&#x02019;s disease (PD)<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>. During the degradations of various biogenic neurotransmitters catalysed by MAO-A and MAO-B, hydrogen peroxide and reactive oxygen species (ROS) are produced as major by-products, which might cause oxidative damage in brain tissues. MAO inhibitors are considered potential neuroprotective agents and up-regulating agents for neurotransmitter amines<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. Numerous studies have documented that selective and reversible/irreversible MAO-B inhibitors are likely to play pivotal roles in AD-related therapeutic strategies. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors also play significant roles in the maintenance of cholinergic functions and are used to provide symptomatic relief in AD. Over the past two decades, many researchers have tried to develop multi-acting MAO-B and AChE/BChE inhibitors<xref rid="CIT0007" ref-type="bibr"><sup>7&#x02013;10</sup></xref>.</p><p>Morpholine is a tetrahydro-1,4-oxazine with a saturated heterocyclic ring and provides a promising developmental starting point due to its biological profile with metabolic stability. The presence of a heteroatom like oxygen or nitrogen facilitates hydrogen bonding, and thus, interactions with enzymes, and the presence of electron-deficient atoms may also impart hydrophobic interactions with morpholine. From the synthetic perspective, various molecular scaffolds have been added to morpholine by replacing its secondary nitrogen<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>. Moclobemide (1) and reboxetine (2) (both antidepressants) provide examples of FDA-approved drugs containing the morpholine moiety (<xref ref-type="fig" rid="F0001">Figure 1</xref>). These drugs reversibly inhibit MAO-A and selectively inhibit norepinephrine reuptake in the central nervous system (CNS), and thus, block the human a4b2 nicotinic acetylcholine receptor. In addition, more than 20 drugs containing the morpholine moiety have been FDA approved; they include mycophenolate mofetil (an immunosuppressant), linezolid and finafloxacin (antibiotics), geftinib (an antineoplastic and epidermal growth factor inhibitor), rivaroxaban (an anticoagulant and factor Xa inhibitor), and eteplirsen, which is used to treat Duchenne muscular dystrophy<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>. Considering the importance of morpholine nucleus, it is worthwhile to design morpholine derived compounds of medicinal chemistry interest.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Morpholine-containing, CNS active, FDA approved drugs. 1, moclobemide; 2, reboxetine.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_F0001_C"/></fig><p>The chalcones framework is considered an excellent starting point for the design for MAO-B and AChE enzyme inhibitors<xref rid="CIT0013" ref-type="bibr"><sup>13&#x02013;15</sup></xref>. The presence of an &#x003b1;-&#x003b2; unsaturated ketone and three rotatable bonds in chalcones can provide different bonding orientations<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>. The literature amply demonstrates that most chalcones are potent, reversible and selective MAO-B inhibitors<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>. In addition, the presence and orientation of various electron-donating and withdrawing groups on the phenyl/heteroaryl <bold>A</bold> and <bold>B</bold> rings of chalcones can impart electrophilic character to the Michael acceptor present. The introductions of electron-donating/lipophilic halogens onto the phenyl <bold>B</bold> ring of chalcones have resulted in the syntheses of highly selective MAO-B inhibitors<xref rid="CIT0018" ref-type="bibr"><sup>18&#x02013;27</sup></xref>. Many studies have reported that the presence of various alkylamino groups on the <bold>A</bold> ring provides AChE inhibitory activity<xref rid="CIT0028" ref-type="bibr"><sup>28&#x02013;31</sup></xref>. The FDA-approved drugs like flurbiprofen and rivastigmine linked with chalcone moiety were developed as selective ChE/MAO-B inhibitors for the prophylactic agents for AD<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>. The design strategy of the current study is depicted in <xref ref-type="fig" rid="F0002">Figure 2</xref> and the synthetic route is shown in <xref ref-type="scheme" rid="s0001">Scheme 1</xref>. A recent study showed that the presence of a pendant morpholine ring on the chalcone <bold>A</bold> ring favoured hMAO-B inhibitory activity<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. The difference in MAO-B inhibition profiles became more obvious when chalcone <bold>B</bold> ring was substituted using a fluoro or trifluoromethyl group<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>.</p><fig id="s0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>The synthetic route used to produce the target compounds (<bold>MO1&#x02013;MO9</bold>).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_SCH0001_C"/></fig><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>MTDL design of MAO-B and AChE inhibitors.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_F0002_C"/></fig></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Results and discussion</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Chemistry</title><p>Morpholine-containing &#x003b1;,&#x003b2;-unsaturated ketones were prepared by condensation between various aromatic/<italic>para</italic> substituted aldehydes and 4-morpholine acetophenone in the presence of an alcoholic basic medium<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>. The H<sup>1</sup> NMR showed that the ring protons N-CH<sub>2</sub> and O-CH<sub>2</sub> of morpholine ring resonated at 3.32&#x02013;3.31 and 3.75&#x02013;3.88&#x02009;ppm as triplets, respectively. The large coupling constant (<italic>J&#x02009;=</italic>&#x02009;15&#x02009;Hz) value of H&#x003b1; and H&#x003b2; protons confirmed the <italic>trans</italic> configuration of the morpholine chalcones. The deshielded values between 186.88&#x02013;186.07 in C<sup>13</sup>-NMR clearly evidenced the formation of sp<sup>2</sup> carbonyl functional group of &#x003b1;,&#x003b2;-unsaturated ketones. The identities of the compounds were determined by <sup>1</sup>H-NMR, <sup>13&#x02009;</sup>C-NMR and Mass spectrometry (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1842390">Supplementary materials</ext-link>).</p></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Analysis of enzyme inhibitory activities</title><sec id="S0002-S2002-S3001" disp-level="3"><label>2.2.1.</label><title>Inhibitory activities</title><p>In this study, nine morpholine-based compounds (<bold>MO1</bold>&#x02013;<bold>MO9</bold>) were analysed with respect to their abilities to inhibit MAO-A, MAO-B and AChE. Most of the compounds inhibited MAO-B by &#x0223c; 50% at 1.0&#x02009;&#x000b5;M, except <bold>MO3</bold> and <bold>MO5</bold> (<xref rid="t0001" ref-type="table">Table 1</xref>). Compound <bold>MO1</bold> most potently inhibited MAO-B (IC<sub>50</sub> = 0.030&#x02009;&#x000b5;M), followed by <bold>MO7</bold>, <bold>MO8</bold>, <bold>MO4</bold>, <bold>MO9</bold>, <bold>MO6</bold>, <bold>MO2</bold>, <bold>MO3</bold> and <bold>MO5</bold> (IC<sub>50</sub> = 0.25, 0.32, 0.33, 0.36, 0.64, 0.70, 1.01 and 1.31&#x02009;&#x000b5;M, respectively). In addition, <bold>MO5</bold> most potently inhibited AChE (IC<sub>50</sub> = 6.1&#x02009;&#x000b5;M), followed by <bold>MO9</bold> and <bold>MO8</bold> (IC<sub>50</sub> = 12.01 and 12.07&#x02009;&#x000b5;M, respectively). <bold>MO7</bold> most potently inhibited MAO-A (IC<sub>50</sub> = 7.1&#x02009;&#x000b5;M), followed by <bold>MO6</bold> (IC<sub>50</sub> = 8.7&#x02009;&#x000b5;M). <bold>MO5</bold> most potently inhibited BChE (IC<sub>50</sub> = 18.09&#x02009;&#x000b5;M), with weaker inhibitory activity compared to AChE, followed by <bold>MO7</bold> (IC<sub>50</sub> = 24.83&#x02009;&#x000b5;M) (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Inhibitions of MAO-A, MAO-B, and AChE by <bold>MO1&#x02013;MO9</bold><sup>a</sup></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Compounds</th><th colspan="4" align="center">Residual activities (%)<hr/></th><th colspan="4" align="center">IC<sub>50</sub> (&#x000b5;M)<hr/></th><th rowspan="2" align="center">SI<sup>b</sup></th></tr><tr><th align="center">MAO-A (10 &#x000b5;M)</th><th align="center">MAO-B (1.0 &#x000b5;M)</th><th align="center">AChE (10 &#x000b5;M)</th><th align="center">BChE (10 &#x000b5;M)</th><th align="center">MAO-A</th><th align="center">MAO-B</th><th align="center">AChE</th><th align="center">BChE</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>MO1</bold></td><td align="char" char="&#x000b1;">94.2&#x02009;&#x000b1;&#x02009;0.62</td><td align="char" char="&#x000b1;">38.1&#x02009;&#x000b1;&#x02009;9.50</td><td align="char" char="&#x000b1;">53.4&#x02009;&#x000b1;&#x02009;0.99</td><td align="char" char="&#x000b1;">62.85&#x02009;&#x000b1;&#x02009;2.97</td><td align="center">&#x0003e;40</td><td align="char" char="&#x000b1;">0.030&#x02009;&#x000b1;&#x02009;0.062</td><td align="char" char="&#x000b1;">16.1&#x02009;&#x000b1;&#x02009;2.24</td><td align="center">&#x0003e;40</td><td align="char" char=".">&#x0003e;1333.3</td></tr><tr><td align="left"><bold>MO2</bold></td><td align="char" char="&#x000b1;">93.8&#x02009;&#x000b1;&#x02009;1.34</td><td align="char" char="&#x000b1;">54.5&#x02009;&#x000b1;&#x02009;5.28</td><td align="char" char="&#x000b1;">72.3&#x02009;&#x000b1;&#x02009;1.34</td><td align="char" char="&#x000b1;">63.55&#x02009;&#x000b1;&#x02009;3.30</td><td align="center">&#x0003e;40</td><td align="char" char="&#x000b1;">0.70&#x02009;&#x000b1;&#x02009;0.23</td><td align="char" char="&#x000b1;">30.2&#x02009;&#x000b1;&#x02009;3.24</td><td align="center">&#x0003e;40</td><td align="char" char=".">&#x0003e; 57.1</td></tr><tr><td align="left"><bold>MO3</bold></td><td align="char" char="&#x000b1;">91.0&#x02009;&#x000b1;&#x02009;3.17</td><td align="char" char="&#x000b1;">79.9&#x02009;&#x000b1;&#x02009;5.28</td><td align="char" char="&#x000b1;">79.3&#x02009;&#x000b1;&#x02009;2.82</td><td align="char" char="&#x000b1;">56.78&#x02009;&#x000b1;&#x02009;2.97</td><td align="center">&#x0003e;40</td><td align="char" char="&#x000b1;">1.01&#x02009;&#x000b1;&#x02009;0.08</td><td align="center">&#x0003e;40</td><td align="center">&#x0003e;40</td><td align="char" char=".">&#x0003e;39.6</td></tr><tr><td align="left"><bold>MO4</bold></td><td align="char" char="&#x000b1;">70.2&#x02009;&#x000b1;&#x02009;1.24</td><td align="char" char="&#x000b1;">49.0&#x02009;&#x000b1;&#x02009;1.45</td><td align="char" char="&#x000b1;">66.0&#x02009;&#x000b1;&#x02009;8.79</td><td align="char" char="&#x000b1;">80.30&#x02009;&#x000b1;&#x02009;6.43</td><td align="center">25.8&#x02009;&#x000b1;&#x02009;1.58</td><td align="char" char="&#x000b1;">0.33&#x02009;&#x000b1;&#x02009;0.03</td><td align="char" char="&#x000b1;">28.42&#x02009;&#x000b1;&#x02009;0.02</td><td align="center">&#x0003e;40</td><td align="char" char=".">78.2</td></tr><tr><td align="left"><bold>MO5</bold></td><td align="char" char="&#x000b1;">88.1&#x02009;&#x000b1;&#x02009;3.43</td><td align="char" char="&#x000b1;">58.6&#x02009;&#x000b1;&#x02009;3.39</td><td align="char" char="&#x000b1;">34.5&#x02009;&#x000b1;&#x02009;9.51</td><td align="char" char="&#x000b1;">60.86&#x02009;&#x000b1;&#x02009;1.07</td><td align="center">&#x0003e;40</td><td align="char" char="&#x000b1;">1.31&#x02009;&#x000b1;&#x02009;0.26</td><td align="char" char="&#x000b1;">6.1&#x02009;&#x000b1;&#x02009;0.0048</td><td align="center">18.09&#x02009;&#x000b1;&#x02009;0.38</td><td align="char" char=".">&#x0003e;30.5</td></tr><tr><td align="left"><bold>MO6</bold></td><td align="char" char="&#x000b1;">12.3&#x02009;&#x000b1;&#x02009;1.58</td><td align="char" char="&#x000b1;">64.1&#x02009;&#x000b1;&#x02009;1.37</td><td align="char" char="&#x000b1;">76.9&#x02009;&#x000b1;&#x02009;3.54</td><td align="char" char="&#x000b1;">70.96&#x02009;&#x000b1;&#x02009;0.36</td><td align="center">8.7&#x02009;&#x000b1;&#x02009;1.32</td><td align="char" char="&#x000b1;">0.64&#x02009;&#x000b1;&#x02009;0.04</td><td align="center">&#x0003e;40</td><td align="center">&#x0003e;40</td><td align="char" char=".">13.6</td></tr><tr><td align="left"><bold>MO7</bold></td><td align="char" char="&#x000b1;">&#x02212;16.5&#x02009;&#x000b1;&#x02009;4.53</td><td align="char" char="&#x000b1;">26.1&#x02009;&#x000b1;&#x02009;5.44</td><td align="char" char="&#x000b1;">65.3&#x02009;&#x000b1;&#x02009;1.55</td><td align="char" char="&#x000b1;">70.21&#x02009;&#x000b1;&#x02009;4.76</td><td align="center">7.1&#x02009;&#x000b1;&#x02009;0.41</td><td align="char" char="&#x000b1;">0.25&#x02009;&#x000b1;&#x02009;0.05</td><td align="char" char="&#x000b1;">20.48&#x02009;&#x000b1;&#x02009;1.10</td><td align="center">24.83&#x02009;&#x000b1;&#x02009;0.34</td><td align="char" char=".">28.4</td></tr><tr><td align="left"><bold>MO8</bold></td><td align="char" char="&#x000b1;">83.7&#x02009;&#x000b1;&#x02009;4.02</td><td align="char" char="&#x000b1;">34.6&#x02009;&#x000b1;&#x02009;5.44</td><td align="char" char="&#x000b1;">50.6&#x02009;&#x000b1;&#x02009;3.61</td><td align="char" char="&#x000b1;">74.61&#x02009;&#x000b1;&#x02009;0.73</td><td align="center">&#x0003e;40</td><td align="char" char="&#x000b1;">0.32&#x02009;&#x000b1;&#x02009;0.16</td><td align="char" char="&#x000b1;">12.07&#x02009;&#x000b1;&#x02009;1.18</td><td align="center">&#x0003e;40</td><td align="char" char=".">&#x0003e;125.0</td></tr><tr><td align="left"><bold>MO9</bold></td><td align="char" char="&#x000b1;">79.8&#x02009;&#x000b1;&#x02009;1.54</td><td align="char" char="&#x000b1;">51.3&#x02009;&#x000b1;&#x02009;2.42</td><td align="char" char="&#x000b1;">50.4&#x02009;&#x000b1;&#x02009;2.42</td><td align="char" char="&#x000b1;">70.21&#x02009;&#x000b1;&#x02009;5.50</td><td align="center">&#x0003e;40</td><td align="char" char="&#x000b1;">0.36&#x02009;&#x000b1;&#x02009;0.16</td><td align="char" char="&#x000b1;">12.01&#x02009;&#x000b1;&#x02009;2.13</td><td align="center">&#x0003e;40</td><td align="char" char=".">&#x0003e;111.1</td></tr><tr><td align="left">Toloxatone</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">1.08&#x02009;&#x000b1;&#x02009;0.025</td><td align="char" char="&#x000b1;">&#x02014;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">&#x000a0;</td><td align="char" char=".">&#x000a0;</td></tr><tr><td align="left">Lazabemide</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">&#x02014;</td><td align="char" char="&#x000b1;">0.063&#x02009;&#x000b1;&#x02009;0.015</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">&#x000a0;</td><td align="char" char=".">&#x000a0;</td></tr><tr><td align="left">Clorgyline</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">0.007&#x02009;&#x000b1;&#x02009;0.00070</td><td align="char" char="&#x000b1;">&#x02014;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">&#x000a0;</td><td align="char" char=".">&#x000a0;</td></tr><tr><td align="left">Pargyline</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">&#x02014;</td><td align="char" char="&#x000b1;">0.028&#x02009;&#x000b1;&#x02009;0.0043</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">&#x000a0;</td><td align="char" char=".">&#x000a0;</td></tr><tr><td align="left">Tacrine</td><td align="char" char="&#x000b1;">&#x03000;</td><td align="char" char="&#x000b1;">&#x03000;</td><td align="char" char="&#x000b1;">&#x03000;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="center">&#x000a0;</td><td align="char" char="&#x000b1;">&#x000a0;</td><td align="char" char="&#x000b1;">0.27&#x02009;&#x000b1;&#x02009;0.019</td><td align="center">0.060&#x02009;&#x000b1;&#x02009;0.0022</td><td align="char" char=".">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label><sup>a</sup></label><p>Values above are the means&#x02009;&#x000b1;&#x02009;SEs of duplicate or triplicate experiments.</p></fn><fn id="TF2"><label><sup>b</sup></label><p>SI&#x02009;=&#x02009;IC<sub>50</sub> of MAO-A/IC<sub>50</sub> of MAO-B.</p></fn><fn id="TF3"><p>AChE values &#x0200b;were determined after pre-incubation compounds and enzymes for 15&#x02009;min.</p></fn></table-wrap-foot></table-wrap><p>Morpholine-containing compounds in this study shared a 1&#x02013;(4-morpholinophenyl) prop-2-en-1-one structure. Introduction of various electron-donating and withdrawing groups onto the <italic>para</italic> position of the phenyl <bold>B</bold> ring of the basic chalcone scaffold afforded different derivatives. Surprisingly, unsubstituted <bold>MO1</bold> inhibited MAO-B more potently than the other eight derivatives. All nine derivatives exhibited MAO-B selectivity. In particular, <bold>MO1</bold> (IC<sub>50</sub> = 0.030&#x02009;&#x000b5;M) was &#x0223c;2 times more potent than the reversible MAO-B inhibitor lazabemide (IC<sub>50</sub> = 0.063&#x02009;&#x000b5;M), and had a high selectivity index (SI = &#x0003e;1333.3), which meant that it was the best inhibitor in the series. Regarding MAO-B inhibition, <bold>MO1</bold> was slightly less potent than the reference irreversible MAO-B inhibitor pargyline (IC<sub>50</sub> = 0.028&#x02009;&#x000b5;M). The presence of dimethylamino, chloro and bromo substituents at the <italic>para</italic> position of the chalcone <bold>B</bold> ring conferred moderate AChE inhibition. Recently, it was reported that shifting of morpholine ring to the phenyl <bold>B</bold> ring of chalcones showed moderate AChE inhibition<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>. Results of SAR analysis of MAO-B/AChE inhibitions by the nine compounds are provided in <xref ref-type="fig" rid="F0003">Figure 3</xref>.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>SAR analysis of MAO-B and AChE inhibitors.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_F0003_C"/></fig></sec><sec id="S0002-S2002-S3002" disp-level="3"><label>2.2.2.</label><title>Kinetics of MAO-B inhibition</title><p>Lineweaver&#x02013;Burk plots and secondary plots of MAO-B inhibition by <bold>MO1</bold> showed that <bold>MO1</bold> is a mixed inhibitor of MAO-B (<italic>K<sub>i</sub></italic> = 0.018&#x02009;&#x000b1;&#x02009;0.002) (<xref ref-type="fig" rid="F0004">Figure 4(A,B)</xref>). These results suggested that <bold>MO1</bold> binds to an allosteric site other than the substrate-binding site of MAO-B.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Lineweaver&#x02013;Burk plots of MAO-B inhibition by <bold>MO1</bold> (A), and respective secondary plots (B) of slopes vs. inhibitor concentrations.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_F0004_C"/></fig></sec><sec id="S0002-S2002-S3003" disp-level="3"><label>2.2.3.</label><title>Kinetics of AChE inhibitions</title><p>Lineweaver&#x02013;Burk plots and secondary plots showed that <bold>MO5</bold> and <bold>MO9</bold> competitively and non-competitively, respectively, inhibited AChE (<xref ref-type="fig" rid="F0005">Figure 5(A,C)</xref>) with <italic>K<sub>i</sub></italic> values of 2.52&#x02009;&#x000b1;&#x02009;0.17 and 7.04&#x02009;&#x000b1;&#x02009;0.32&#x02009;&#x000b5;M, respectively (<xref ref-type="fig" rid="F0005">Figure 5(B,D)</xref>), which suggest that <bold>MO5</bold> is a potent, selective and competitive inhibitor of AChE that binds to the active site of AChE, and that <bold>MO9</bold> binds to a site other than the active site of AChE and changes the 3D structure of the enzyme, thus inhibiting enzyme activity.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Lineweaver&#x02013;Burk plots of AChE inhibition by <bold>MO5</bold> (A) and <bold>MO9</bold> (C), and respective secondary plots (B and D) of slopes vs. inhibitor concentrations.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_F0005_C"/></fig></sec><sec id="S0002-S2002-S3004" disp-level="3"><label>2.2.4.</label><title>Analysis of the reversibilities of MAO-B and AChE inhibitions</title><p>Inhibition assays were carried out after preincubating MAO-B or AChE with the inhibitors for 15&#x02009;min. The reversibilities of MAO-B inhibition by <bold>MO1</bold> and of AChE inhibitions by <bold>MO5</bold> and <bold>MO9</bold> were investigated by dialysis<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. Dialysis recovered the inhibition of MAO-B by <bold>MO1</bold> from 21.6% (<italic>A</italic><sub>U</sub>) to 77.1% (<italic>A</italic><sub>D</sub>), which was similar to that shown by lazabemide (from 38.8 to 90.0%), a reversible MAO-B inhibitor (<xref ref-type="fig" rid="F0006">Figure 6(A)</xref>). On the other hand, inhibition of MAO-B by pargyline (an irreversible inhibitor) was recovered from 10.7 to 16.5%. In addition, inhibitions of AChE by <bold>MO5</bold> and <bold>MO9</bold> were recovered by dialysis from 35.8% (A<sub>U</sub>) to 79.2% (A<sub>D</sub>) and from 33.8 to 80.7%, respectively, which were similar to that observed for tacrine (from 32.8 to 91.7%), a reversible AChE inhibitor (<xref ref-type="fig" rid="F0006">Figure 6(B)</xref>). These results indicate that <bold>MO1</bold> is a reversible inhibitor of MAO-B, and that <bold>MO5</bold> and <bold>MO9</bold> are reversible inhibitors of AChE.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Dialysis recoveries of MAO-B inhibition by <bold>MO1</bold> (A) and AChE inhibition by <bold>MO5</bold> and <bold>MO9</bold> (B). The concentrations of the inhibitors used were approximately 2&#x02009;&#x000d7;&#x02009;IC<sub>50</sub> values: <bold>MO1</bold>, 0.06&#x02009;&#x000b5;M; <bold>MO5</bold>, 12.0&#x02009;&#x000b5;M; <bold>MO9</bold>, 24.0&#x02009;&#x000b5;M; lazabemide, 0.12&#x02009;&#x000b5;M; pargyline, 0.06&#x02009;&#x000b5;M; and tacrine, 0.54&#x02009;&#x000b5;M (tacrine was used as a reference reversible inhibitor). For recovery experiments, preincubated enzyme mixtures were dialysed as described in the text.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_F0006_C"/></fig></sec></sec><sec id="S0002-S2003" disp-level="2"><label>2.3.</label><title>Blood&#x02013;brain barrier (BBB) permeation</title><p>The synthesised derivatives were screened for their abilities to cross the BBB using the parallel artificial membrane permeability assay (PAMPA) because this ability is a critical developmental requirement for any drug targeting neurodegenerative disorders or depression. The PAMPA used was validated by comparing the experimentally determined permeabilities of eight commercial drugs with reported values (<xref rid="t0002" ref-type="table">Table 2</xref>). According to reported BBB permeation limits, compounds were classified as follows:<xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref> CNS+ (high): Pe (10<sup>&#x02212;6&#x02009;</sup>cm s<sup>&#x02212;1</sup>) &#x0003e; 4.00, CNS- (low): Pe (10<sup>&#x02212;6&#x02009;</sup>cm s<sup>&#x02212;1</sup>) &#x0003c;2.00 and CNS&#x000b1; (uncertain): Pe (10<sup>&#x02212;6&#x02009;</sup>cm s<sup>&#x02212;1</sup>) from 4.00 to 2.00. Our results suggest that all nine synthesised derivatives could cross the BBB, and that <bold>MO1</bold>, <bold>MO5</bold> and <bold>MO9</bold> would be the most effective.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Experimental membrane permeabilities of the synthetic and reference inhibitors.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Compounds</th><th align="center">Bibliography<break/>Pe (&#x000d7;10<sup>&#x02212;6</sup> cm s<sup>&#x02212;1</sup>)</th><th align="center">Experimental<break/>Pe (&#x000d7;10<sup>&#x02212;6</sup> cm s<sup>&#x02212;1</sup>)</th><th align="center">Prediction</th></tr></thead><tbody valign="top"><tr><td align="left">Testosterone</td><td align="char" char=".">17.0</td><td align="char" char="&#x000b1;">16.86&#x02009;&#x000b1;&#x02009;0.67</td><td align="left">CNS+</td></tr><tr><td align="left">Verapamil</td><td align="char" char=".">16.0</td><td align="char" char="&#x000b1;">15.69&#x02009;&#x000b1;&#x02009;0.44</td><td align="left">CNS+</td></tr><tr><td align="left">&#x003b2;-estradiol</td><td align="char" char=".">12.0</td><td align="char" char="&#x000b1;">11.88&#x02009;&#x000b1;&#x02009;0.53</td><td align="left">CNS+</td></tr><tr><td align="left">Progesterone</td><td align="char" char=".">9.3</td><td align="char" char="&#x000b1;">9.10&#x02009;&#x000b1;&#x02009;0.11</td><td align="left">CNS+</td></tr><tr><td align="left">Piroxicam</td><td align="char" char=".">2.5</td><td align="char" char="&#x000b1;">2.35&#x02009;&#x000b1;&#x02009;0.30</td><td align="left">CNS+/-</td></tr><tr><td align="left">Hydrocortisone</td><td align="char" char=".">1.8</td><td align="char" char="&#x000b1;">1.71&#x02009;&#x000b1;&#x02009;0.05</td><td align="left">CNS-</td></tr><tr><td align="left">Lomefloxacin</td><td align="char" char=".">1.1</td><td align="char" char="&#x000b1;">1.26&#x02009;&#x000b1;&#x02009;0.01</td><td align="left">CNS-</td></tr><tr><td align="left">Dopamine</td><td align="char" char=".">0.2</td><td align="char" char="&#x000b1;">0.21&#x02009;&#x000b1;&#x02009;0.01</td><td align="left">CNS-</td></tr><tr><td align="left"><bold>MO1</bold></td><td align="center">&#x02014;</td><td align="char" char="&#x000b1;">16.34&#x02009;&#x000b1;&#x02009;0.16</td><td align="left">CNS+</td></tr><tr><td align="left"><bold>MO5</bold></td><td align="center">&#x02014;</td><td align="char" char="&#x000b1;">14.44&#x02009;&#x000b1;&#x02009;0.81</td><td align="left">CNS+</td></tr><tr><td align="left"><bold>MO9</bold></td><td align="center">&#x02014;</td><td align="char" char="&#x000b1;">14.61&#x02009;&#x000b1;&#x02009;0.08</td><td align="left">CNS+</td></tr></tbody></table></table-wrap></sec><sec id="S0002-S2004" disp-level="2"><label>2.4.</label><title>Cytotoxic studies</title><p>The biocompatibilities of <bold>MO1, MO5</bold> and <bold>MO9</bold> were investigated using an MTT (3&#x02013;(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and normal VERO cells<xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref>,<xref rid="CIT0038" ref-type="bibr"><sup>38</sup></xref>. Results showed that <bold>MO1, MO5</bold> and <bold>MO9</bold> were non-toxic to normal VERO cells with IC<sub>50</sub> values of 195.14, 185.44 and 188.34&#x02009;&#x000b5;g/mL, respectively, indicating that the therapeutic potentials of these compounds would be suitable.</p></sec><sec id="S0002-S2005" disp-level="2"><label>2.5.</label><title>Total ROSs assay</title><p>ROS are considered to be the radicals primarily responsible for the neuronal death observed in various neurodegenerative disorders<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>. The lead compounds <bold>MO1, MO5</bold> and <bold>MO9</bold> were subjected to ROS assays using Hela cells. ROS levels significantly increased in H<sub>2</sub>O<sub>2</sub>-treated Hela cells as determined by fluorescent image analyses (<xref ref-type="fig" rid="F0007">Figure 7(B)</xref>). <bold>MO1</bold> and <bold>MO5</bold> (<xref ref-type="fig" rid="F0007">Figure 7(C,D)</xref>) at 40&#x02009;&#x000b5;g/mL resulted in significantly lower ROS levels than <bold>MO9</bold> (<xref ref-type="fig" rid="F0007">Figure 7(E)</xref>). Interestingly, the colony formation induced by H<sub>2</sub>O<sub>2</sub> was markedly reduced by the lead MAO-B inhibitor <bold>MO1</bold>, which suggested that the molecule can be highly recommended for the arrest of free radicals in the neurodegenerative disorders.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Inhibition of H<sub>2</sub>O<sub>2</sub>-induced ROS generation in human cervical cancer cells. (A) Treatment-na&#x000ef;ve control cells; (B) Cells treated with 100&#x02009;&#x003bc;g/mL of H<sub>2</sub>O<sub>2</sub>; (C) Cells treated with 40&#x02009;&#x003bc;g/mL of <bold>MO1</bold>; (D) Cells treated with 40&#x02009;&#x003bc;g/mL of <bold>MO5</bold>; (E) Cells- treated with 40&#x02009;&#x003bc;g/mL of <bold>MO9</bold>.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_F0007_C"/></fig></sec><sec id="S0002-S2006" disp-level="2"><label>2.6.</label><title>Computational studies</title><p>Initially, <bold>MO1</bold> and <bold>MO5</bold> were used as bases for profiling the pharmacological spectra of putative protein targets using the free web platform MuSSel<xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref>. Interestingly, MAO-B and AChE were predicted to be 13th and 14th targets for <bold>MO1</bold> and 7th and 15th targets for <bold>MO5</bold>, respectively. Details are provided in Supporting Information.</p><p>Docking studies were performed on <bold>MO1</bold> and <bold>MO5</bold> using the X-ray resolved structures of MAO-A, MAO-B and AChE in the Protein Data Bank (PDB) as entries 2Z5X, 2VZ5 and 4EY7<xref rid="CIT0042" ref-type="bibr"><sup>42&#x02013;45</sup></xref>. Docking protocols were performed as we described in a previous study<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>. Molecular docking simulations were performed to investigate interactions between <bold>MO1</bold> and <bold>MO5</bold> and MAO-A, MAO-B and AChE. The docking scores resulting from <italic>in silico</italic> simulations are reported in <xref rid="t0003" ref-type="table">Table 3</xref>. Results showed that the carbonyl and the 4-morpholin-phenyl groups of the chalcone scaffolds of <bold>MO1</bold> and <bold>MO5</bold> hydrogen-bonded with F295 and formed &#x003c0;&#x02009;&#x02212;&#x02009;&#x003c0; interactions with the side chain of W286 at the peripheral anionic subsite (PAS) of AChE (<xref ref-type="fig" rid="F0008">Figure 8(A)</xref>). Also, the dimethylamino group of <bold>MO5</bold> established a weak hydrophobic interaction with W86 at the catalytic anionic subsite (CAS). <bold>MO1</bold> and <bold>MO5</bold> formed &#x003c0;&#x02009;&#x02212;&#x02009;&#x003c0; interactions with the selective MAO-B residue Y326 (<xref ref-type="fig" rid="F0008">Figure 8(B)</xref>). In addition, the styryl and dimethylaminophenyl groups of <bold>MO1</bold> and <bold>MO5</bold>, respectively, established &#x003c0;&#x02013;&#x003c0; interactions with Y398 and were sandwiched within an aromatic cage formed by Y328, Y435 and FAD. <bold>MO1</bold> engaged in a &#x003c0;&#x02009;&#x02212;&#x02009;&#x003c0; interaction with Y407 and was entangled in a hydrophobic cage consisting of Y407, Y444 and FAD of MAO-A (<xref ref-type="fig" rid="F0008">Figure 8(C)</xref>), whereas <bold>MO5</bold> established &#x003c0;&#x02013;&#x003c0; interactions with a selective MAO-A residue F208 using its 4-morpholine-phenyl group. In order to point out the selectivity of <bold>MO1</bold> and <bold>MO5</bold>, molecular docking analyses were performed on BChE crystal structure. Docking score values of <bold>MO1</bold> and <bold>MO5</bold> for BChE were worse than those for AChE (<xref rid="t0003" ref-type="table">Table 3</xref>). Interestingly, <bold>MO1</bold> and <bold>MO5</bold> can predominantly establish hydrophobic interactions in the BChE binding pocket; in particular <bold>MO1</bold> engaged a &#x003c0;&#x02013;&#x003c0; interaction with F329, but both compounds cannot make crucial interactions with the catalytic W82 residue (<xref ref-type="fig" rid="F0008">Figure 8(D)</xref>).</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>Top scored poses of <bold>MO1</bold> and <bold>MO5</bold> for binding with AChE (A), MAO-B (B) and MAO-A (C) are shown on left and right sides, respectively. <bold>MO1</bold>, <bold>MO5</bold> and key enzyme residues are displayed as green, yellow and grey sticks, respectively. Green and red arrows indicate &#x003c0;&#x02013;&#x003c0; interactions and hydrogen bonds, respectively.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1842390_F0008_C"/></fig><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Docking score values for bindings between <bold>MO1</bold> and <bold>MO5</bold> and MAO-B or AChE.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Compounds</th><th colspan="3" align="center">Docking score (kcal/mol)<hr/></th></tr><tr><th align="center">AChE</th><th align="center">MAO-B</th><th align="center">BChE</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>MO1</bold></td><td align="char" char=".">&#x02212;10.31</td><td align="char" char=".">&#x02212;8.67</td><td align="left">&#x02212;7.42</td></tr><tr><td align="left"><bold>MO5</bold></td><td align="char" char=".">&#x02212;10.12</td><td align="char" char=".">&#x02212;9.34</td><td align="left">&#x02212;6.66</td></tr></tbody></table></table-wrap><p>Overall, computational analyses provided a sound explanation of the experimental data. Docking scores and the binding modes obtained demonstrated that <bold>MO1</bold> and <bold>MO5</bold> can meaningfully interact with MAO-B as indicated by IC<sub>50</sub> experimental values. Interestingly, even if <bold>MO1</bold> had adopted a similar binding mode in MAO-A and MAO-B binding pockets, the two docking score values would have been quite different, due to a lack of &#x003c0;&#x02013;&#x003c0; interaction with the MAO-A selective residue F208 and lesser hydrophobic interactions. On the other hand, <bold>MO5</bold> assumed a switched pose within the MAO-A binding pocket, with its morpholine ring facing FAD, presumably because the dimethylamino substituent on the phenyl ring did not allow adequate access to the binding site. As regards AChE, molecular docking awarded a better score for <bold>MO5</bold> than <bold>MO1</bold>, which also agreed with experimental data, despite the resemblance between their binding poses.</p></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Conclusion</title><p>We describe the synthesis of morpholine-containing &#x003b1;,&#x003b2;-unsaturated ketones, and the results of an investigation of their MAOs and AChE inhibition profiles. Most of the nine compounds synthesised exhibited potent MAO-B inhibition with moderate AChE inhibition. Interestingly, <bold>MO1</bold> (the lead compound) inhibited MAO-B inhibition in the low nanomolar range and was more potent than lazabemide (the reference compound). The low cytotoxicity and the ability of <bold>MO1</bold> to transit the BBB support our drug design strategy. In addition, the ROS scavenging efficacy of <bold>MO1</bold> suggests improved neuroprotective effects.</p></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Experimental</title><sec id="S0004-S2001" disp-level="2"><label>4.1.</label><title>Enzyme assays</title><p>MAO-A activity was measured continuously for 20&#x02009;min at 316&#x02009;nm using 0.06&#x02009;mM kynuramine as substrate, as described previously<xref rid="CIT0046" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref>, whereas MAO-B activity was measured for 30&#x02009;min at 250&#x02009;nm using 0.3&#x02009;mM benzylamine as substrate. MAO activity assays were performed using recombinant human MAO-A or MAO-B. A slightly modified version of the method developed by Ellman<xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref> was used to measure AChE and BChE activities, using 0.5&#x02009;mM acetylthiocholine iodide (ATCI) and <italic>S</italic>-butyrylthiocholine iodide (BTCI), respectively, as substrates for 10&#x02009;min at 412&#x02009;nm<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>. Colour development was performed using 0.5&#x02009;mM 5,5&#x02032;-dithiobis (2-nitrobenzoic acid) (DTNB), which reacts with thiocholine (a product of ATCI by AChE or of BTCI by BChE) to produce 5-thio 2-nitrobenzoic acid. Preincubation was treated for 15&#x02009;min before adding ATCI and DTNB.</p></sec><sec id="S0004-S2002" disp-level="2"><label>4.2.</label><title>Analysis of enzyme inhibitions and kinetics</title><p>MAO-A, MAO-B, AChE and BChE activities were measured after exposure to inhibitors at a concentration of 10&#x02009;&#x000b5;M. Inhibitions of MAO-B at 10&#x02009;&#x000b5;M of these compounds tested were too excessive, and thus, a concentration of 1.0&#x02009;&#x000b5;M was used. IC<sub>50</sub> values were determined by measuring the residual enzyme activities. Toloxatone, lazabemide and tacrine, were used as reference reversible inhibitors of MAO-A, MAO-B and AChE, respectively, and clorgyline and pargyline as reference irreversible inhibitors of MAO-A and MAO-B, respectively. <italic>K<sub>i</sub></italic> values and inhibitor types were determined by kinetic testing, as previously described<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>. Kinetic tests were conducted at 5 different substrate concentrations, and the inhibitor concentrations used were 0, &#x0223c;1/2&#x02009;&#x000d7;&#x02009;IC<sub>50</sub>, IC<sub>50</sub>, and 2&#x02009;&#x000d7;&#x02009;IC<sub>50</sub> values. Lineweaver&#x02013;Burk plots and their secondary plots were used to determine <italic>K<sub>i</sub></italic> values and inhibitor types.</p></sec><sec id="S0004-S2003" disp-level="2"><label>4.3.</label><title>Analysis of inhibitor reversibilities</title><p>Inhibition types (reversible or irreversible) were determined by dialysis, as previously described<sup>51,52</sup>, but by using 0.06&#x02009;mM kynuramine and 0.3&#x02009;mM benzylamine. For the experiment of AChE, 0.5&#x02009;mM ATCI was used. Dialysis experiments were performed by preincubating enzymes and inhibitors (or reference inhibitors) at &#x0223c;2&#x02009;&#x000d7;&#x02009;IC<sub>50</sub> in 0.1&#x02009;M sodium phosphate buffer (pH 7.2) for 30&#x02009;min, and then dialysing solutions with stirring for 6&#x02009;h with a buffer change at 3&#x02009;h. Residual activities were calculated using the measured activities of undialyzed (A<sub>U</sub>) and dialysed (A<sub>D</sub>) solutions and the activities of untreated controls (i.e. without inhibitor).</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM5440"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_1842390_SM5440.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#x000ed;guez-Soacha</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Scheiner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Decker</surname><given-names>M.</given-names></name></person-group>
<article-title>Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>180</volume>:<fpage>690</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">31401465</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name></person-group>
<article-title>Multi-target design strategies for the improved treatment of Alzheimer's disease</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>176</volume>:<fpage>228</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">31103902</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Dias</surname><given-names>KST</given-names></name>, <name name-style="western"><surname>Gontijo</surname><given-names>VS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Multi-target directed drugs as a modern approach for drug design towards Alzheimer's disease: an update</article-title>. <source>Curr Med Chem</source>
<year>2018</year>;<volume>25</volume>:<fpage>3491</fpage>&#x02013;<lpage>525</lpage>.<pub-id pub-id-type="pmid">29332563</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youdim</surname><given-names>MBH</given-names></name>, <name name-style="western"><surname>Buccafusco</surname><given-names>JJ.</given-names></name></person-group>
<article-title>Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders</article-title>. <source>Trends Pharmacol Sci</source>
<year>2005</year>;<volume>26</volume>:<fpage>27</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">15629202</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Silvestri</surname><given-names>R.</given-names></name></person-group>
<article-title>New frontiers in selective human MAO-B inhibitors</article-title>. <source>J Med Chem</source>
<year>2015</year>;<volume>58</volume>:<fpage>6717</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">25915162</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rehuman</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jat</surname><given-names>RK</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A comprehensive review of monoamine oxidase-A inhibitors in their syntheses and potencies</article-title>. <source>Comb Chem High Throughput Screen</source>
<year>2020</year>;<volume>23</volume>:<fpage>898</fpage>&#x02013;<lpage>914</lpage>.<pub-id pub-id-type="pmid">32342809</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Parambi</surname><given-names>DGT</given-names></name>, <name name-style="western"><surname>Mathew</surname><given-names>GE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases</article-title>. <source>Arch Pharm (Weinheim)</source>
<year>2019</year>;<volume>352</volume>:<fpage>e1900177</fpage>.<pub-id pub-id-type="pmid">31478569</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>HY.</given-names></name></person-group>
<article-title>One-compound-multiple-targets strategy to combat Alzheimer's disease</article-title>. <source>FEBS Lett</source>
<year>2005</year>;<volume>579</volume>:<fpage>5260</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">16194540</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ortuso</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Petzer</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>143</volume>:<fpage>1543</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">29126727</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Secci</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Petzer</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>597</fpage>&#x02013;<lpage>612</lpage>.<pub-id pub-id-type="pmid">30727777</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzara</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Xanthopoulos</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kourounakis</surname><given-names>AP.</given-names></name></person-group>
<article-title>Morpholine as a scaffold in medicinal chemistry: An update on synthetic strategies</article-title>. <source>ChemMedChem</source>
<year>2020</year>;<volume>15</volume>:<fpage>392</fpage>&#x02013;<lpage>403</lpage>.<pub-id pub-id-type="pmid">32017384</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kourounakis</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Xanthopoulos</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tzara</surname><given-names>A.</given-names></name></person-group>
<article-title>Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules</article-title>. <source>Med Res Rev</source>
<year>2020</year>;<volume>40</volume>:<fpage>709</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">31512284</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeta</surname></name><name><surname>Baek</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Rangarajan</surname><given-names>TM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ethyl acetohydroxamate incorporated chalcones: Unveiling a novel class of chalcones for multitarget monoamine oxidase-B inhibitors against Alzheimer&#x02019;s disease</article-title>. <source>CNS Neurol Disord Drug Targets</source>
<year>2019</year>;<volume>18</volume>:<fpage>643</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">31550216</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guglielmi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Secci</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S.</given-names></name></person-group>
<article-title>Chalcones: unearthing their therapeutic possibility as monoamine oxidase B inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>205</volume>:<fpage>112650</fpage>.<pub-id pub-id-type="pmid">32920430</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Parambi</surname><given-names>DGT</given-names></name>, <name><surname>Sivasankarapillai</surname></name><name><surname>Uddin</surname><given-names>MS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Perspective design of chalcones for the management of CNS disorders: a mini-review</article-title>. <source>CNS Neurol Disord Drug Targets</source>
<year>2019</year>;<volume>18</volume>:<fpage>432</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">31187716</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Sheng</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chalcone: a privileged structure in medicinal chemistry</article-title>. <source>Chem Rev</source>
<year>2017</year>;<volume>117</volume>:<fpage>7762</fpage>&#x02013;<lpage>810</lpage>.<pub-id pub-id-type="pmid">28488435</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Haridas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Suresh</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Monoamine oxidase inhibitory action of chalcones: a mini review</article-title>. <source>Cent Nerv Syst Agents Med Chem</source>
<year>2016</year>;<volume>16</volume>:<fpage>120</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">26429556</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chimenti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Fioravanti</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bolasco</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chalcones: a valid scaffold for monoamine oxidases inhibitors</article-title>. <source>J Med Chem</source>
<year>2009</year>;<volume>52</volume>:<fpage>2818</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">19378991</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mathew</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>U&#x000e7;ar</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: synthesis, biochemistry and molecular docking studies</article-title>. <source>Bioorg Chem</source>
<year>2015</year>; <volume>62</volume>:<fpage>22</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26189013</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>U&#x000e7;ar</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mathew</surname><given-names>GE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Monoamine oxidase inhibitory activity: methyl-versus chlorochalcone derivatives</article-title>. <source>Chem Med Chem</source>
<year>2016</year>;<volume>11</volume>:<fpage>2649</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">27902880</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Haridas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>U&#x000e7;ar</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, biochemistry, and computational studies of brominated thienyl chalcones: a new class of reversible MAO-B inhibitors</article-title>. <source>Chem Med Chem</source>
<year>2016</year>;<volume>11</volume>:<fpage>1161</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">27159243</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammuda</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shalaby</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rovida</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>114</volume>:<fpage>162</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26974383</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parambi</surname><given-names>DGT</given-names></name>, <name name-style="western"><surname>Oh</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>SC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biological evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>93</volume>:<fpage>103335</fpage>.<pub-id pub-id-type="pmid">31606547</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakshminarayan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Kannappan</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ethoxylated head of chalcones as a new class of multi-targeted MAO inhibitors</article-title>. <source>Chem Select</source>
<year>2019</year>;<volume>4</volume>:<fpage>6614</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shalaby</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Petzer</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Petzer</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>863</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">30915862</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name></person-group>
<article-title>Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and reversible inhibitors of human monoamine oxidase B</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1513</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">32705910</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Rangarajan</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Reeta</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors</article-title>. <source>Molecules</source>
<year>2020</year>;<volume>20</volume>:<fpage>2536</fpage>.</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors</article-title>. <source>Bioorg Med Chem</source>
<year>2017</year>;<volume>25</volume>:<fpage>360</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">27856236</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Qiang</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease</article-title>. <source>Bioorg Med Chem</source>
<year>2017</year>;<volume>25</volume>:<fpage>1030</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">28011206</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment</article-title>. <source>Bioorg Med Chem</source>
<year>2018</year>;<volume>26</volume>:<fpage>1102</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">29409707</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Qiang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Q</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Flurbiprofen-chalcone hybrid mannich base derivatives as balanced multifunctional agents against Alzheimer&#x02019;s disease: design, synthesis and biological evaluation</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>94</volume>:<fpage>103447</fpage>.<pub-id pub-id-type="pmid">31810756</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B.</given-names></name></person-group>
<article-title>Privileged pharmacophore of FDA approved drugs in combination with chalcone framework: a new hope for Alzheimer's treatment</article-title>. <source>Comb Chem High Throughput Screen</source>
<year>2020</year>;<volume>23</volume>:<fpage>842</fpage>&#x02013;<lpage>846</lpage>.<pub-id pub-id-type="pmid">32723232</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Parambi</surname><given-names>DGT</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: fluorinated chalcones of morpholine versus imidazole</article-title>. <source>Arch Pharm</source>
<year>2019</year>;<volume>352</volume>:<fpage>e1800309</fpage>.</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maliyakkal</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Eom</surname><given-names>BH</given-names></name>, <name name-style="western"><surname>Heo</surname><given-names>JH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new potent and selective monoamine oxidase-B inhibitor with extended conjugation in a chalcone framework: 1-[4-(morpholin-4-yl)&#x0200c;phenyl]-5-phenylpenta-2,4-dien-1-one</article-title>. <source>ChemMedChem</source>
<year>2020</year>;<volume>15</volume>:<fpage>1629</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">32583952</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Nicol Ibarra-Arellano</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Prent-Penalozaa</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ultrasound-assisted synthesis of novel chalcone, heterochalcone and bis-chalcone derivatives and the evaluation of their antioxidant properties and as acetylcholinesterase inhibitors</article-title> . <source>Bioorg Chem</source>
<year>2019</year>;<volume>90</volume>:<fpage>103034</fpage>.<pub-id pub-id-type="pmid">31280015</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kerns</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>High throughput artificial membrane permeability assay for blood-brain barrier</article-title>. <source>Eur J Med Chem</source>
<year>2003</year>;<volume>38</volume>:<fpage>223</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">12667689</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suresh</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Ramakrishnan</surname><given-names>SP</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of potent and reversible MAO-B inhibitors as furanochalcones</article-title>. <source>Int J Biol Macromol</source>
<year>2018</year>;<volume>108</volume>:<fpage>660</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">29195801</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dev</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Parambi</surname><given-names>DGT</given-names></name>, <name name-style="western"><surname>Baby</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>An environment-friendly synthesis of piperonal chalcones and their cytotoxic and antioxidant evaluation</article-title>. <source>Lett Drug Des Drug Discov</source>
<year>2020</year>;<volume>17</volume>:<fpage>138</fpage>&#x02013;<lpage>44</lpage>.</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cha</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>SH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Protective effects of phloroglucinol on oxidative stress&#x02013;induced DNA damage and apoptosis through activation of the Nrf2/HO-1 signaling pathway in HaCaT human keratinocytes</article-title>. <source>Mar Drugs</source>
<year>2019</year>;<volume>17</volume>:<fpage>225</fpage>.</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montaruli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Alberga</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ciriaco</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Accelerating drug discovery by early protein drug target prediction based on multi-fingerprint similarity search</article-title>. <source>Molecules</source>
<year>2019</year>;<volume>24</volume>:<fpage>2233</fpage>.</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberga</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Trisciuzzi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Montaruli</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new approach for drug target and bioactivity prediction: the multifingerprint similarity search algorithm (MuSSeL)</article-title>. <source>J Chem Inf Model</source>
<year>2019</year>;<volume>59</volume>:<fpage>586</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">30485097</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kondou</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2008</year>;<volume>105</volume>:<fpage>5739</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">18391214</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binda</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pisani</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs</article-title>. <source>J Med Chem</source>
<year>2007</year>;<volume>50</volume>:<fpage>5848</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">17915852</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rudolph</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Burshteyn</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structures of human acetylcholinesterase in complex with pharmacologically important ligands</article-title>. <source>J Med Chem</source>
<year>2012</year>;<volume>55</volume>:<fpage>10282</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23035744</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko&#x00161;ak</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Brus</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Knez</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Development of an in-vivo active reversible butyrylcholinesterase inhibitor</article-title>. <source>Sci Rep</source>
<year>2016</year>;<volume>6</volume>:<fpage>39495</fpage><pub-id pub-id-type="pmid">28000737</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Grace Thomas Parambi</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors</article-title>. <source>MedChemComm</source>
<year>2018</year>;<volume>9</volume>:<fpage>1871</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">30568755</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Ryu</surname><given-names>HW</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Rhamnocitrin isolated from <italic>Prunus padus</italic> var. seoulensis: a potent and selective reversible inhibitor of human monoamine oxidase A</article-title>. <source>Bioorg Chem</source>
<year>2018</year>;<volume>28</volume>:<fpage>317</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellman</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Courtney</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Andres</surname><given-names>V</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Feather-Stone</surname><given-names>RM.</given-names></name></person-group>
<article-title>A new and rapid colorimetric determination of acetylcholinesterase activity</article-title>. <source>Biochem Pharmacol</source>
<year>1961</year>;<volume>7</volume>:<fpage>88</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">13726518</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Potent inhibition of acetylcholinesterase by sargachromanol I from <italic>Sargassum</italic> siliquastrum and by selected natural compounds</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>89</volume>:<fpage>103043</fpage>.<pub-id pub-id-type="pmid">31200287</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Ryu</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>MG</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of <italic>Sophora flavescens</italic></article-title>. <source>Bioorg Med Chem Lett</source>
<year>2016</year>;<volume>26</volume>:<fpage>4714</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27575476</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Ryu</surname><given-names>HW</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selective inhibition of monoamine oxidase A by hispidol</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2018</year>;<volume>15</volume>:<fpage>58</fpage>&#x02013;<lpage>588</lpage>.</mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasidharan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Manju</surname><given-names>SL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors</article-title>. <source>Biomed Pharmacother</source>
<year>2018</year>;<volume>106</volume>:<fpage>8</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">29940538</pub-id></mixed-citation></ref></ref-list></back></article>